X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3967) 3967
Book Review (1044) 1044
Publication (443) 443
Book Chapter (39) 39
Conference Proceeding (7) 7
Dissertation (7) 7
Paper (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3370) 3370
humans (2664) 2664
male (1854) 1854
non-alcoholic fatty liver disease (1806) 1806
animals (1543) 1543
fatty liver (1412) 1412
liver diseases (1207) 1207
female (1178) 1178
gastroenterology & hepatology (1093) 1093
liver (1038) 1038
insulin-resistance (1032) 1032
non-alcoholic fatty liver disease - drug therapy (935) 935
insulin resistance (929) 929
metabolic syndrome (876) 876
middle aged (865) 865
obesity (857) 857
liver - metabolism (842) 842
liver - pathology (833) 833
mice (798) 798
nonalcoholic steatohepatitis (731) 731
adult (718) 718
steatohepatitis (712) 712
non-alcoholic fatty liver disease - metabolism (711) 711
fatty liver-disease (707) 707
fibrosis (676) 676
hepatic steatosis (676) 676
risk factors (668) 668
liver - drug effects (663) 663
steatosis (637) 637
inflammation (628) 628
non-alcoholic fatty liver disease - pathology (603) 603
oxidative stress (562) 562
nafld (501) 501
non-alcoholic steatohepatitis (473) 473
fatty liver - drug therapy (460) 460
analysis (456) 456
diet (447) 447
rats (443) 443
rodents (441) 441
disease models, animal (437) 437
mice, inbred c57bl (434) 434
pharmacology & pharmacy (423) 423
metabolism (418) 418
nonalcoholic fatty liver disease (417) 417
prevalence (404) 404
aged (402) 402
diabetes (398) 398
gastroenterology and hepatology (388) 388
endocrinology & metabolism (383) 383
non-alcoholic fatty liver disease - complications (369) 369
disease (366) 366
care and treatment (355) 355
fatty liver - metabolism (350) 350
fatty acids (348) 348
non-alcoholic fatty liver disease - etiology (343) 343
lipids (336) 336
health aspects (334) 334
liver cirrhosis (331) 331
non-alcoholic fatty liver disease - blood (330) 330
insulin (325) 325
treatment outcome (325) 325
fatty liver - pathology (324) 324
biopsy (318) 318
biochemistry & molecular biology (316) 316
nutritional and metabolic diseases (312) 312
physiological aspects (295) 295
non-alcoholic fatty liver disease - diagnosis (291) 291
digestive system diseases (290) 290
glucose (290) 290
hepatology (284) 284
cholesterol (278) 278
diet, high-fat - adverse effects (275) 275
nutrition & dietetics (275) 275
article (274) 274
research (273) 273
hepatocellular-carcinoma (269) 269
type 2 diabetes (268) 268
cirrhosis (267) 267
nash (265) 265
expression (263) 263
non-alcoholic fatty liver disease - epidemiology (260) 260
gene expression (259) 259
development and progression (257) 257
body mass index (256) 256
medicine (252) 252
triglycerides (251) 251
disease progression (248) 248
non-alcoholic fatty liver disease - genetics (247) 247
medicine, research & experimental (246) 246
lipid metabolism (243) 243
pathogenesis (243) 243
obesity - complications (242) 242
research article (242) 242
lipid metabolism - drug effects (241) 241
hepatitis (235) 235
vitamin-e (235) 235
biomarkers - blood (233) 233
fatty liver - etiology (231) 231
non-alcoholic fatty liver disease - therapy (231) 231
medical research (229) 229
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3846) 3846
Chinese (54) 54
Russian (29) 29
German (14) 14
Spanish (11) 11
Ukrainian (10) 10
Japanese (9) 9
French (7) 7
Hungarian (6) 6
Korean (6) 6
Czech (2) 2
Italian (2) 2
Dutch (1) 1
Persian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 5, pp. 1147 - 1159.e5
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9972, pp. 956 - 965
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 08/2015, Volume 114, Issue 5, pp. 796 - 803
Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus... 
Clinical trials | Inflammation | Fatty liver | Non-alcoholic fatty liver disease | Resveratrol | METABOLIC SYNDROME | ACTIVATED PROTEIN-KINASE | SENSITIVITY | RATS | TRIAL | SYNBIOTIC SUPPLEMENTATION | NUTRITION & DIETETICS | PROFILE | INSULIN-RESISTANCE | MOUSE MODEL | GLUCOSE-TOLERANCE | Stilbenes - therapeutic use | Plant Extracts - pharmacology | Humans | Middle Aged | Fatty Liver - complications | Male | Alanine Transaminase - blood | Stilbenes - pharmacology | Non-alcoholic Fatty Liver Disease - complications | Non-alcoholic Fatty Liver Disease - blood | Liver - drug effects | Anti-Inflammatory Agents - therapeutic use | Cardiovascular Diseases - blood | Adult | Female | Blood Pressure - drug effects | Phytotherapy | Cardiovascular Diseases - etiology | Fatty Liver - metabolism | Cardiovascular Diseases - metabolism | Double-Blind Method | Anti-Inflammatory Agents - pharmacology | Fatty Liver - blood | Liver - metabolism | Risk Factors | Insulin Resistance | Lipid Metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Antioxidants - pharmacology | Biomarkers - blood | Fatty Liver - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Antioxidants - therapeutic use | Triglycerides - blood | Dietary Supplements | Plant Extracts - therapeutic use | Liver diseases | Dietary supplements | Cardiovascular disease | Health risk assessment | Fatty acids | Placebo effect | Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2015, Volume 125, Issue 1, pp. 386 - 402
Journal Article
Diabetes care, ISSN 0149-5992, 08/2018, Volume 41, Issue 8, pp. 1801 - 1808
OBJECTIVE Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodentmodels. Data regarding the effect of SGLT-2... 
FIBROSIS | METAANALYSIS | SELECTIVE INHIBITOR IPRAGLIFLOZIN | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | RISK | AMINOTRANSFERASE LEVELS | STEATOHEPATITIS | HEPATIC STEATOSIS | TRANSCRIPTION FACTOR | ASSOCIATION | Humans | Middle Aged | Male | Alanine Transaminase - blood | Diabetes Mellitus, Type 2 - metabolism | Non-alcoholic Fatty Liver Disease - complications | Adipose Tissue - metabolism | Liver - drug effects | Liver - diagnostic imaging | Adult | Female | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Adiposity - drug effects | Liver - metabolism | Treatment Outcome | Adipose Tissue - diagnostic imaging | Non-alcoholic Fatty Liver Disease - metabolism | Non-alcoholic Fatty Liver Disease - drug therapy | Magnetic Resonance Imaging | Aspartate Aminotransferases - blood | Diabetes Mellitus, Type 2 - drug therapy | Adipose Tissue - drug effects | Type 2 diabetes | Usage | Fatty liver | Magnetic resonance imaging | Liver | Drug therapy | Health aspects | Animal models | Alanine | Liver diseases | Body fat | Diabetes mellitus | Proton density (concentration) | Transaminase | Clinical trials | Glucose | Disease control | Patients | Risk factors | Inhibitors | Sodium | Aspartate transaminase | Alanine transaminase | Research design | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 09/2016, Volume 165, Issue 5, pp. 305 - 315
Journal Article
Journal Article